Hello, Guest!
  • Thursday, April 25, 2024

Emergent BioSolutions Gets $1.25 Billion Contract to Supply Anthrax Vaccine

The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five years on a contract worth up to $1.25 billion.

Contract work will begin this year and calls for Emergent to deliver a total of 44.75 million doses of BioThrax. In the first contract year, 8.5 million doses are scheduled to be delivered. The vaccine will be delivered through September 2016.

The U.S. Food and Drug Administration has licensed BioThrax to protect against anthrax infection.

“This five-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs, ” said Emergent CEO Fuad El-Hibri.

Video of the Day

Related Articles

HHS to Back Emergent BioSolutions’ Ebola Drug Development With Potential $704M Award Contract Awards

HHS to Back Emergent BioSolutions’ Ebola Drug Development With Potential $704M Award

Emergent BioSolutions (NYSE: EBS) will further develop a licensed drug against Ebola under a potential 10-year, $704 million contract from the Department of Health and Human Services. Development services on Ebanga under the contract are valued at $121 million and the award includes a five-year option worth $583 million for the U.S. government to procure

Emergent BioSolutions Books $628M HHS COVID-19 Vaccine Manufacturing Task Order Contract Awards

Emergent BioSolutions Books $628M HHS COVID-19 Vaccine Manufacturing Task Order

The Department of Health and Human Services has awarded Gaithersburg, Md.-based biopharmaceutical company Emergent BioSolutions a $628M task order to support the production of potential vaccines for the novel coronavirus through 2021.

Emergent Lands $535M HHS Smallpox Preparedness Support Contract Contract Awards

Emergent Lands $535M HHS Smallpox Preparedness Support Contract

Emergent BioSolutions (NYSE: EBS) has received a potential 10-year, $535M contract to supply the Department of Health and Human Services with intravenous medications designed to treat patients experiencing adverse events following smallpox vaccination. The company said Monday it will provide Vaccinia Immune Globulin Intravenous products that HHS intends to include in the U.S. Strategic National Stockpile as part of public health preparedness efforts.